Inhibition of Pathological Angiogenesis of Chinese Medicine against Liver Fibrosis

Pathological angiogenesis of liver which includes liver sinusoidal capillarization due to lose of fenestraes of liver sinusoidal endothelial cells (LSECs) and formation of new vascular, is a crucial mechanism responsible for origination and development of liver fifibrosis and closely involves in the development of cirrhosis and hepatic cancer. Anti-neovascularization medicine such as sorafenib can decrease portosystemic shunts, improve splanchnic hyperdynamic circulation, lower portal hypertension, while it can not be applied in clinic due to its serious toxic and side reactions. Chinese herbal formula can effectively inhibit pathological angiogenesis of liver, improve microcirculation of liver, and decrease the probability of gastrointestinal hemorrhage in cirrhotic patients. Different Chinese herbal formula are of different characteristics on inhibiting pathological angiogenesis in liver fifibrosis, which partly explains synergistic effect of different compatibility of Chinese materia medica and opens up good vista for Chinese medicine against liver fifibrosis through inhibiting angiogenesis.     

Research Progress of Angiogenesis in Atherosclerotic Plaque in Chinese Medicine and Western Medicine

Angiogenesis in atherosclerotic plaque plays a critical role in the mechanism of atherosclerotic physiopathology. Present consensus shows that angiogenesis in atherosclerotic plaque is mainly resulted in hypoxia, inflammation and some pro-angiogenic factors. The homeostasis in plaque, which is hypoxic and infiltrated by inflammatory cells, may lead to angiogenesis, increase the plaque instability and the incidence rate of vascular events. This article reviews the progression of pathogenetic mechanism, physiopathological significance, relevant detecting technique and corresponding therapeutic methods of Chinese and Western medicine of angiogenesis in atherosclerotic plaque, so as to provide more theoretical basis for atherosclerotic clinical treatment.     

肝星状细胞活化的炎性调控机制及中药抗纤维化研究进展

肝纤维化是细胞外基质的过度沉积为主要特征的损伤后修复反应,包括炎症及其后的纤维生成。肝星状细胞（HSC）的激活是肝纤维化发生的中心环节,而肝脏中多种炎性细胞与炎症相关因子是调节HSC激活及其后的纤维化发生发展的关键因素,涉及的分子机制亦十分复杂。中医药抗纤维化的研究从20世纪70年代中期开始,随着细胞生物学与分子生物学技术的应用,中医药抗纤维化机制的阐明也越来越深入。     

单味药治疗肝纤维化研究进展

中医药抗肝纤维化日益成为关注的焦点,而现代中医不仅要了解传统中药的功效,还要对单味中药的现代药理研究有更全面的了解,这样对于临床用药辨证治疗会起到极其重要的作用,文章将常用的治疗肝纤维化的中药从现代药理研究的角度作以综述。     

血管再生：中医药治疗中风的新方向

Based on the pathophysiology of the brain, advance in angiogenesis induced by stroke, and evidences of Chinese-medicine-mediated angiogenesis, the possibility to study the stroke-treating mechanism of Chinese medicine in angiogenesis was discussed. And regarding our previous work on angiogenesis modulated by qi-tonifying and stasis-eliminating therapy following intracerebral hemorrhage, we proposed some questions, which should be taken into account in the further work.     

中医药防治肾纤维化的研究现状及实践

肾纤维化是各种慢性肾脏病进展至终末期肾病的病理基础,可危及生命。其发病机制较为复杂,由多种细胞因子和信号通路共同参与。目前尚无有效治疗药物。近年来基于肾纤维化的中医理论及其分子机制,通过随机多中心临床研究以及体内外基础研究,证实多种中药及其有效成分有延缓肾纤维化的疗效,并明确了作用靶点。继续寻找有效的延缓肾纤维化的中药,证实其疗效,明确作用机制尤为重要。<     

复方中药对兔血吸虫病肝纤维化指标的影响

目的 评价中药抗血吸虫病肝纤维化的效果。方法 用日本血吸虫尾蚴感染新西兰白兔，造成肝纤维化模型。12周后服吡喹酮杀虫治疗，继以复方中药煎剂灌胃，并与秋水仙碱及生理盐水组(对照组)比较，观察血清前胶原Ⅱ(PCⅡ)、Ⅳ型胶原(Ⅳ—C)、透明质酸(HA)、层粘连蛋白(LN)的含量，并用天狼红染色及免疫组化法观察肝组织胶原蛋白的沉积、分布和含量；用原位杂交检测肝组织I型前胶原mRNA的表达。结果 中药组、秋水仙碱组血清纤维指标较病理对照组显著下降，肝组织胶原蛋白含量和I型胶原mRNA的表达也明显减少，但均未降至正常对照组水平。结论 补气、活血类复方中药具有较好的抗血吸虫病肝纤维化作用。     

中药抗肾间质纤维化机制研究

肾间质纤维化由多种病理机制造成,包括成纤维细胞过度活化、肾小管上皮细胞转分化等等,中药可以通过干预其中某一或多种途径而起到抗肾纤维化作用。     

补肾益气化瘀解毒汤抗肝纤维化的临床观察

目的?观察补肾益气化瘀解毒汤抗肝纤维化作用。方法?临床选择98例肝纤维化患者,随机分为2组各49例,对照组口服鳖甲软肝片,治疗组服用补肾益气化瘀解毒汤,治疗6月后观测其临床疗效、中医证候积分、肝肾功能、肝纤维化指标、肝脾B超等指标的变化。结果?治疗后,治疗组总有效率明显高于对照组（P<0.01）;2组中医证候积分,均明显下降（P<0.05~0.01）,治疗组优于对照组（P<0.01）。治疗组谷丙转氨酶（ALT）、谷草转氨酶（AST）、总胆红素（TBIL）、白蛋白（ALB）含量明显下降（P<0.01）,明显优于对照组（P<0.01）;治疗组透明质酸（HA）、Ⅳ型胶原（Ⅳ-C）、Ⅲ型前胶原(PCⅢ)水平明显下降（P<0.01）,明显优于对照组（P<0.01）。治疗组门静脉、脾静脉内径及脾脏厚度明显缩小（P<0.05~0.01）,明显优于对照组（P<0.01）;治疗组肝脏硬度值明显下降,优于对照组（P<0.01）。结论?补肾益气化瘀解毒汤抗肝纤维化效果确切。      

中药注射液治疗特发性肺纤维化有效性及安全性系统评价

目的 系统评价中药注射液联合西医常规治疗特发性肺纤维化的有效性及安全性.方法 全面检索6个电子数据库中关于中药注射液联合西医常规治疗特发性肺纤维化的随机对照试验.检索时间为各数据库建库起至2019年8月为止.对检索到的文献由两名独立的研究者分别进行筛选文献、提取数据、评价文献质量及评估偏倚风险,若有分歧则协商解决,否则...     

中西医治疗甲状腺机能亢进症合并肝功能损害

甲状腺机能亢进症合并肝功能损害(甲亢性肝损)在临床中较常见,治疗也比较棘手。西医目前对甲亢性肝损的治疗主要有:使用抗甲药物、激素治疗及保肝治疗;中医药在治疗方面有着一定的特点。文章对目前中西医治疗甲亢性肝损的研究进展及优缺点进行综述。     

中医药调节肝纤维化相关因子的研究进展

肝纤维化发生、发展过程中和体内多种细胞因子合成与功能失调有关。肝星状细胞的激活、表型改变并分泌大量的细胞外基质是肝纤维化发生的中心环节。而细胞因子在肝星状细胞的活化、表型改变中扮演重要角色。目前中医药对肝纤堆化相关因子的研究取得一定进展。     

中西医抗肿瘤血管生成治疗非小细胞肺癌研究现状

肿瘤血管生成与肿瘤生长、浸润和转移密切相关。近年来以肿瘤血管生成为靶点的肿瘤血管生成抑制剂成为当前治疗非小细胞肺癌的研究热点,中医药在抗肿瘤血管生成方面的作用亦受到广泛的关注。因此文章就中西医抗肿瘤血管生成治疗非小细胞肺癌的相关研究进行系统阐述。     

Effectiveness and Safety of Chinese Medicine for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis

Objective: To evaluate the effectiveness and safety of Chinese medicine(CM) for Idiopathic pulmonary fibrosis(IPF) patients. Methods: To screened relevant articles, Pub Med, Cochrane Library, Excerpta Medica Datase(EMBASE), China National Knowledge Infrastructure(CNKI), Chinese VIP Information(VIP), Wanfang Database and Chinese Biomedical Database(CBM) were searched in English or Chinese until December 2015 for randomized controlled trials, which compared CM treatment(CM group) with Western medicine or placebo(control group) on IPF. The outcome measures included acute exacerbation, pulmonary function, the St George's respiratory questionnaire(SGRQ) scores, 6-minute walk test(6 MWT) distance, adverse events and mortality. Results: This meta-analysis included 25 randomized controlled trials involving 1,471 patients. Compared with the control group, CM group was superiori in reducing the risk of exacerbation [relative risk(RR)=0.40, 95% CI 0.22 to 0.72, P0.05], improving in forced expiratory volume in one second(FEV1) [standard mean difference(SMD)=0.62, 95% CI 0.40 to 0.84, P0.01] and diffusion capacity for carbon monoxide(DLCO, SMD=0.40, 95% CI 0.22 to 0.58, P0.01), but there was no significant difference in vital capacity(VC, SMD=0.10, 95% CI –0.12 to 0.31, P0.05). This meta-analysis also revealed that CM therapy significantly decreased the SGRQ score(SMD=–0.60, 95% CI –1.14 to –0.05, P0.05) and improved 6 MWT distance(SMD=0.59, 95% CI 0.34 to 0.84, P0.01), compared with the control group. Meanwhile, CM therapy was associated with a low incidence of adverse effects(RR=0.19, 95% CI 0.08 to 0.43, P0.01). However, there was no significant difference in mortality(RR=0.24, 95% CI 0.05 to 1.10, P0.05) between CM and control groups. Conclusions: The pooled outcomes suggest that CM treatment appears benefit in reducing the risk of exacerbation, improving lung function and decreasing the incidence of adverse effects and enhancing the quality of life. However, the outcomes were limited because of the low quality of the included studies. More rigorous clinic trials need to be carried out to provide sufficient and accurate evidence in the future.     

中西医抗肿瘤血管生成治疗非小细胞肺癌研究现状

肿瘤血管生成与肿瘤生长、浸润和转移密切相关。近年来以肿瘤血管生成为靶点的肿瘤血管生成抑制剂成为当前治疗非小细胞肺癌的研究热点,中医药在抗肿瘤血管生成方面的作用亦受到广泛的关注。因此文章就中西医抗肿瘤血管生成治疗非小细胞肺癌的相关研究进行系统阐述。     

中医药抗肝纤维化的研究现状及前景

从相关文献及临床与基础研究方面,分析中医药抗肝纤维化的研究现状,并简要阐述中医药抗肝纤维化急需解决的问题,以及研究前景。     

硬皮病中西医治疗的研究进展

综述近年来硬皮病的发病机制与中西医治疗方法.硬皮病是一种主要累及皮肤、黏膜组织并以纤维化和硬化为主要特征的结缔组织疾病,自身免疫改变和纤维化是该病的突出特征,其发病机制涉及血管异常、结缔组织异常、免疫改变等.西医治疗硬皮病通常采用药物硝苯地平、泼尼松、波生坦、青霉胺、秋水仙碱、伊洛前列腺素、环磷酰胺、霉酚酸酯等,同时结...     

中西哲学差异对中西医学的影响

中西方不同的经济和地理环境造成了中西哲学的差异,中西哲学就是在两种不同的文化背景下产生的对宇宙人生普遍规律的探求和看法,其视野和着重点都表现出多层次的差异。详细比较了中西哲学的本质差异,总结出了中西哲学的特征,并指出二者的差异深刻影响了两种不同医学认识和处理问题的方法。随着社会的进步和科学的发展,中西传统哲学都面临着前所未有的挑战,二者在彼此融合,互相兼容,取长补短,而中西医结合的发展方向也是一种大势所趋。     

立足中医，开展中西医结合

“中西医结合”已有五十余年,迄今仍遭质疑。中医、西医究竟该怎样结合？文中提出必须立足中医,开展中西医结合,并围绕这一问题进行了阐述。     

探索中西医结合之路

中医与西医如何结合一直是医学界关注的问题,中医是河图易经的发挥,有着清晰的从整体到系统的脉络,西医的发展则是随哲学、数学、物理学、化学等方面的发展而发展的,就目前而言是片面的。中医与西医的结合应该是以系统论、量子力学为沟通前提,以河图易经的逻辑规律为理论依据,有原则地选择双方信息,再加以整合。